Company: MDCXW
Filing Date: 2025-12-30
Form Type: 424B3
Source: 0001062993-25-017506
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-12-30
Form: 424B3
Chunk 2
---
 registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry into a Material Definitive Agreement. On December 29, 2025, Medicus Pharma Ltd. (the "Company") entered into an Equity Distribution Agreement (the "Agreement") with Maxim Group LLC ("Maxim") and Yorkville Securities, LLC ("Yorkville Securities" and together with Maxim, the "Agents") to create an at-the-market equity program. Under the Agreement, the Company may offer and sell its common shares, no par value (the "Shares"), from time to time having an aggregate offering amount of up to $15,349,674 during the term of the Agreement through Maxim or Yorkville Securities, as sales agents. The Company has agreed to pay the Agents a commission equal to 3.0% of the gross sales price from the sales of Shares pursuant to the Agreement. In addition, subject to limitations, the Company has agreed to reimburse the Agents for their reasonable and documented costs and out-of-pocket expenses incurred in connection with their services, including the fees and out-of-pocket expenses of their legal counsel. Sales of the Shares, if any, under the Agreement may be made through any method permitted by law to be "at-the-market equity offerings" as defined in Rule 415 under the Securities Act of 1933, as amended, including sales directly on The Nasdaq Capital Market, at market prices or as otherwise agreed with the Agents. The Company has no obligation to sell any of the Shares under the Agreement and no assurance can be given that the Company will sell any Shares under the Agreement, or if it does, as to the price or amount of Shares that the Company will sell, or the dates on which any such sales will take place. The offering of Shares pursuant to the Agreement will terminate on the sale, pursuant to the Agreement, of Shares having an aggregate offering price of $15,349,674 or by the Company or the Agents in the other circumstances described in the Agreement. The Shares will be issued pursuant to the Company's Registration Statement on Form S-3 filed with the Securities and Exchange Commission ("SEC") on December 29, 2025 (the "Registration Statement") and the prospectus relating to the offer and sale of the Shares that forms a part of the Registration Statement, following such time as the Registration Statement is declared effective by the SEC. The Shares